This study is testing a new treatment called TheraSphere GBM for people with glioblastoma (a type of aggressive brain cancer) that has come back (recurrent). TheraSphere GBM uses tiny glass beads with radiation (yttrium-90) that are delivered directly to the tumor through a catheter (a thin tube) placed in a blood vessel. The goal is to deliver a high dose of radiation to the tumor while limiting side effects to healthy brain tissue. This study wants to see how safe TheraSphere GBM is by looking at serious side effects like non-blood-related issues, brain-specific problems, and radiation damage to the brain within 30 days after treatment. You might be able to join if you are 18 or older, have a confirmed diagnosis of glioblastoma, and are expected to live at least 12 weeks. This study is currently recruiting 36 participants.

Study design

This is a single-arm study, meaning all 36 participants will receive the TheraSphere GBM treatment. It is an interventional study, which means participants will receive a specific treatment.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will follow participants for at least 30 days after the treatment to check for side effects.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.